Filament Health (DB:7QS) - Stock Price, News & Analysis

7QS Stock Overview

Operates as a clinical-stage natural psychedelic drug development company in Canada. More details

7QS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 6% per year over past 5 years

Does not have a meaningful market cap (€8M)

Highly volatile share price over the past 3 months compared to the German market

+ 2 more risks

Filament Health Corp. Competitors

MPH Health Care

DB:93M1

€105.3m

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Valeo Pharma

DB:VP2

€493.4k

Price History & Performance

Summary of all time highs, changes and price drops for Filament Health
Historical stock prices
Current Share Price	US$0.015
52 Week High	US$0.11
52 Week Low	US$0.009
Beta	1
11 Month Change	25.00%
3 Month Change	-21.05%
1 Year Change	-85.00%
33 Year Change	-92.42%
5 Year Change	n/a
Change since IPO	-91.87%

Recent updates

Shareholder Returns

	7QS	DE Pharmaceuticals	DE Market
7D	11.1%	-1.2%	-0.02%
1Y	-85.0%	-20.1%	8.2%

Return vs Industry: 7QS underperformed the German Pharmaceuticals industry which returned -22% over the past year.

Return vs Market: 7QS underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is 7QS's price volatile compared to industry and market?
7QS volatility
7QS Average Weekly Movement	46.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 7QS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7QS's weekly volatility (47%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
n/a	13	Ben Lightburn	filament.health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage.

Filament Health Corp. Fundamentals Summary

How do Filament Health's earnings and revenue compare to its market cap?
7QS fundamental statistics
Market cap	€7.54m
Earnings (TTM)	-€2.85m
Revenue (TTM)	€1.48m

5.1x

P/S Ratio

-2.6x

P/E Ratio

Is 7QS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7QS income statement (TTM)
Revenue	CA$2.16m
Cost of Revenue	CA$0
Gross Profit	CA$2.16m
Other Expenses	CA$6.31m
Earnings	-CA$4.15m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.016
Gross Margin	100.00%
Net Profit Margin	-192.34%
Debt/Equity Ratio	0%

How did 7QS perform over the long term?

See historical performance and comparison

7QS Stock Overview

Risk Analysis

Filament Health Corp. Competitors

DB:93M1

€105.3m

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

DB:VP2

€493.4k

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2023)

Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital

Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder

New major risk - Revenue and earnings growth

Filament Health Corp. Announces Change to Board of Directors

Full year 2023 earnings released: CA$0.028 loss per share (vs CA$0.097 loss in FY 2022)

Recent updates

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2023)

Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital

Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder

New major risk - Revenue and earnings growth

Filament Health Corp. Announces Change to Board of Directors

Full year 2023 earnings released: CA$0.028 loss per share (vs CA$0.097 loss in FY 2022)

Less than half of directors are independent

Filament Health Corp. Announces Chief Financial Officer Changes

Filament Health Corp. Announces Appointment of Michael Messinger to Its Board of Directors and Chair of the Audit Committee

Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel

Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders

Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)

Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder

Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital

Filament Health Corp., Annual General Meeting, Nov 07, 2023

Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010

New minor risk - Shareholder dilution

Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital

Filament Health Announces Clinical Trial Approval in Partnership with Psychiatric Centre Copenhagen

Filament Health Corp. Announces Change to Board of Directors

High number of new and inexperienced directors

Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial

Filament Health Corp. Announces the Appointment of Dr. Konstantin Adamsky to Board of Directors, and Jeff Chilton of Nammex to the Advisory Council

Filament Health Corp. Announces Eighth Patent Issuance

Filament Health Corp. announced that it has received CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital

Filament Health Corp. Receives Third Patent by United States Patent and Trademark Office

Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial

Filament Health Announces Sixth Patent Issuance

Filament Health Corp. announced that it expects to receive CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital

Filament Health Corp. Announces Patient Dosing Through Health Canada Special Access Program

Filament Health Corp. Cultivates 70th Variety of Psilocybin-containing Mushrooms At Its 3,500 Square Foot Gmpcompliant Facility in Metro Vancouver

Filament Health Corp. Issues Second Patent by United States Patent and Trademark Office

Filament Health Corp., Annual General Meeting, Jun 28, 2022

Filament Health Corp. and Cybin Therapeutics Announce Approval for Phase Ii Clinical Trial for Depression

Filament Health Corp. Announces Health Canada Approval for Phase II Clinical Trial Administering New Psilocybin Microdose Formulation

Shareholder Returns

Price Volatility

About the Company

Filament Health Corp. Fundamentals Summary

5.1x

-2.6x

Earnings & Revenue